Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Induction of resident memory T cells enhances the efficacy of cancer vaccine.

Nizard M, Roussel H, Diniz MO, Karaki S, Tran T, Voron T, Dransart E, Sandoval F, Riquet M, Rance B, Marcheteau E, Fabre E, Mandavit M, Terme M, Blanc C, Escudie JB, Gibault L, Barthes FLP, Granier C, Ferreira LCS, Badoual C, Johannes L, Tartour E.

Nat Commun. 2017 May 24;8:15221. doi: 10.1038/ncomms15221.

2.

A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic Mice.

Tran T, Diniz MO, Dransart E, Gey A, Merillon N, Lone YC, Godefroy S, Sibley C, Ferreira LC, Medioni J, Oudard S, Johannes L, Tartour E.

Clin Cancer Res. 2016 Aug 15;22(16):4133-44. doi: 10.1158/1078-0432.CCR-16-0044. Epub 2016 Mar 22.

3.

Gastric Adenocarcinomas Express the Glycosphingolipid Gb3/CD77: Targeting of Gastric Cancer Cells with Shiga Toxin B-Subunit.

Geyer PE, Maak M, Nitsche U, Perl M, Novotny A, Slotta-Huspenina J, Dransart E, Holtorf A, Johannes L, Janssen KP.

Mol Cancer Ther. 2016 May;15(5):1008-17. doi: 10.1158/1535-7163.MCT-15-0633. Epub 2016 Jan 29.

4.

Targeted Shiga toxin-drug conjugates prepared via Cu-free click chemistry.

Kostova V, Dransart E, Azoulay M, Brulle L, Bai SK, Florent JC, Johannes L, Schmidt F.

Bioorg Med Chem. 2015 Nov 15;23(22):7150-7. doi: 10.1016/j.bmc.2015.10.010. Epub 2015 Oct 8.

PMID:
26507432
5.

Vaccine-induced tumor regression requires a dynamic cooperation between T cells and myeloid cells at the tumor site.

Thoreau M, Penny HL, Tan K, Regnier F, Weiss JM, Lee B, Johannes L, Dransart E, Le Bon A, Abastado JP, Tartour E, Trautmann A, Bercovici N.

Oncotarget. 2015 Sep 29;6(29):27832-46. doi: 10.18632/oncotarget.4940.

6.

Retrograde transport is not required for cytosolic translocation of the B-subunit of Shiga toxin.

Garcia-Castillo MD, Tran T, Bobard A, Renard HF, Rathjen SJ, Dransart E, Stechmann B, Lamaze C, Lord M, Cintrat JC, Enninga J, Tartour E, Johannes L.

J Cell Sci. 2015 Jul 1;128(13):2373-87. doi: 10.1242/jcs.169383. Epub 2015 May 14.

7.

A new delivery system for auristatin in STxB-drug conjugate therapy.

Batisse C, Dransart E, Ait Sarkouh R, Brulle L, Bai SK, Godefroy S, Johannes L, Schmidt F.

Eur J Med Chem. 2015 May 5;95:483-91. doi: 10.1016/j.ejmech.2015.03.047. Epub 2015 Mar 28.

PMID:
25847766
8.

Synergy of Radiotherapy and a Cancer Vaccine for the Treatment of HPV-Associated Head and Neck Cancer.

Mondini M, Nizard M, Tran T, Mauge L, Loi M, Clémenson C, Dugue D, Maroun P, Louvet E, Adam J, Badoual C, Helley D, Dransart E, Johannes L, Vozenin MC, Perfettini JL, Tartour E, Deutsch E.

Mol Cancer Ther. 2015 Jun;14(6):1336-45. doi: 10.1158/1535-7163.MCT-14-1015. Epub 2015 Apr 1.

9.

Mucosal imprinting of vaccine-induced CD8⁺ T cells is crucial to inhibit the growth of mucosal tumors.

Sandoval F, Terme M, Nizard M, Badoual C, Bureau MF, Freyburger L, Clement O, Marcheteau E, Gey A, Fraisse G, Bouguin C, Merillon N, Dransart E, Tran T, Quintin-Colonna F, Autret G, Thiebaud M, Suleman M, Riffault S, Wu TC, Launay O, Danel C, Taieb J, Richardson J, Zitvogel L, Fridman WH, Johannes L, Tartour E.

Sci Transl Med. 2013 Feb 13;5(172):172ra20. doi: 10.1126/scitranslmed.3004888. Erratum in: Sci Transl Med. 2013 Mar 27;5(178):178er2. Suleman, Muhammed [corrected to Suleman, Muhammad].

10.

PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer.

Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, Levionnois E, Nizard M, Si-Mohamed A, Besnier N, Gey A, Rotem-Yehudar R, Pere H, Tran T, Guerin CL, Chauvat A, Dransart E, Alanio C, Albert S, Barry B, Sandoval F, Quintin-Colonna F, Bruneval P, Fridman WH, Lemoine FM, Oudard S, Johannes L, Olive D, Brasnu D, Tartour E.

Cancer Res. 2013 Jan 1;73(1):128-38. doi: 10.1158/0008-5472.CAN-12-2606. Epub 2012 Nov 7.

11.

A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens.

Pere H, Montier Y, Bayry J, Quintin-Colonna F, Merillon N, Dransart E, Badoual C, Gey A, Ravel P, Marcheteau E, Batteux F, Sandoval F, Adotevi O, Chiu C, Garcia S, Tanchot C, Lone YC, Ferreira LC, Nelson BH, Hanahan D, Fridman WH, Johannes L, Tartour E.

Blood. 2011 Nov 3;118(18):4853-62. doi: 10.1182/blood-2011-01-329656. Epub 2011 Sep 9.

PMID:
21908423
12.

Tumor delivery of ultrasound contrast agents using Shiga toxin B subunit.

Couture O, Dransart E, Dehay S, Nemati F, Decaudin D, Johannes L, Tanter M.

Mol Imaging. 2011 Apr;10(2):135-43.

PMID:
21439258
13.

In vivo tumor targeting by the B-subunit of shiga toxin.

Viel T, Dransart E, Nemati F, Henry E, Thézé B, Decaudin D, Lewandowski D, Boisgard R, Johannes L, Tavitian B.

Mol Imaging. 2008 Nov-Dec;7(6):239-47.

PMID:
19123994
14.

Intracellular trafficking of Shiga-toxin-B-subunit-functionalized spherulites.

Bouter A, Delord B, Dransart E, Poirier C, Johannes L, van Effenterre D.

Biol Cell. 2008 Dec;100(12):717-25. doi: 10.1042/BC20080009.

PMID:
18564063
15.

RhoGDIs revisited: novel roles in Rho regulation.

Dransart E, Olofsson B, Cherfils J.

Traffic. 2005 Nov;6(11):957-66. Review. Erratum in: Traffic. 2006 Jan;7(1):108.

16.

RhoGDI-3, a promising system to investigate the regulatory function of rhoGDIs: uncoupling of inhibitory and shuttling functions of rhoGDIs.

Dransart E, Morin A, Cherfils J, Olofsson B.

Biochem Soc Trans. 2005 Aug;33(Pt 4):623-6. Review.

PMID:
16042558
17.

Uncoupling of inhibitory and shuttling functions of rho GDP dissociation inhibitors.

Dransart E, Morin A, Cherfils J, Olofsson B.

J Biol Chem. 2005 Feb 11;280(6):4674-83. Epub 2004 Oct 28.

Supplemental Content

Loading ...
Support Center